₹10,825 Cr
--
₹7 Cr
As on 13-Aug-2024 IST
₹51.35
•
4.55%
₹1,127.80
₹1,130.90
₹1,189.00
₹1,127.80
8,03,501
₹412.10 - 1,189.00
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Strides Pharma
| 81.62 | 28.74 | 39.87 | 174.19 | 20.76 | 22.82 | 6.78 |
|
BSE Healthcare
| 30.05 | 6.86 | 18.26 | 46.79 | 16.31 | 26.45 | 12.81 |
|
BSE Small Cap
| 24.81 | -1.39 | 17.32 | 50.92 | 26.42 | 33.21 | 18.27 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Strides Pharma
| 85.58 | -21.74 | -49.28 | 142.87 | -22.35 | -43.87 | -22.52 |
|
BSE Small Cap
| 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 | 59.64 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Strides Pharma Science Ltd stood at ₹ 5,840 Cr as on 30-Jun-24
The share price of Strides Pharma Science Ltd is ₹1,179.15 (NSE) and ₹1,177.20 (BSE) as of 13-Aug-2024 IST. Strides Pharma Science Ltd has given a return of 20.76% in the last 3 years.
Strides Pharma Science Ltd has a market capitalisation of ₹ 10,825 Cr as on 13-Aug-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Strides Pharma Science Ltd is 4.91 times as on 13-Aug-2024, a 19% discount to its peers’ median range of 6.09 times.
Since, TTM earnings of Strides Pharma Science Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Strides Pharma Science Ltd and enter the required number of quantities and click on buy to purchase the shares of Strides Pharma Science Ltd.
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company has a strategic partnership with Orbicular Pharmaceutical Technologies Private Limited to develop, manufacture, and commercialize nasal sprays. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
The promoter of Strides Pharma Science Ltd is PRONOMZ VENTURES LLP. PRONOMZ VENTURES LLP owns 17.18 per cent of the total equity. The chairman of the company is Arun Kumar , and the managing director is Arun Kumar..
The promoters of Strides Pharma Science Ltd have pledged 16.72% of the total equity as on Jun-24.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
11,416
|
|
|
7,981
|
|
|
6,869
|
|
|
3,620
|
| Strides Pharma Science Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
7.37
|
|
Operating margin(%)
|
13.88
|
|
Net Margin(%)
|
1.97
|
|
Dividend yield(%)
|
0.21
|
Yes, TTM profit after tax of Strides Pharma Science Ltd was ₹7 Cr.
₹10,825.32 Cr
₹4,208.64 Cr
₹6.70 Cr
₹296.92 Cr
₹2,774.46 Cr
25.86%
High
₹412.10 - 1,189.00
₹10.00
9,19,58,214
NSE: STAR, BSE: 532531
Navi Mumbai, Maharashtra
www.strides.com
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The... company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company has a strategic partnership with Orbicular Pharmaceutical Technologies Private Limited to develop, manufacture, and commercialize nasal sprays. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India. Read more
Stocks 
Strides Pharma Science Ltd.
Widely used:
